CITIUS ONCOLOGY, INC.(CTOR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CTOR Stock Analysis & AI Quality Score
AI stock analysis and institutional research for CITIUS ONCOLOGY, INC. (CTOR), a Healthcare sector company. CTOR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q2 2026), CITIUS ONCOLOGY, INC. reports quarterly revenue of $1.7M, net income of $-26.6M, free cash flow of $-3.8M. Top institutional holders of CTOR by reported 13-F value include ARMISTICE CAPITAL,, BANK OF AMERICA /DE/, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CTOR trades on the Nasdaq exchange and files with the SEC under CIK 1851484. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTOR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CITIUS ONCOLOGY, INC. directly from SEC EDGAR.
Revenue
Q2 2026
$1.7M
Net Income
Q2 2026
$-26.6M
Free Cash Flow
Q2 2026
$-3.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-17.1% YoYOperating Income
-14.3% YoYEPS (Diluted)
-9.7% YoYTotal Assets
+19.6% YoYOp. Cash Flow
-4446.6% YoY| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Net Income | $-24.8M -17.1% | $-21.1M |
| Operating Income | $-23.5M -14.3% | $-20.6M |
| EPS (Diluted) | $-0.34 -9.7% | $-0.31 |
| Total Assets | $100.9M +19.6% | $84.4M |
| Operating Cash Flow | $-5.5M -4446.6% | $126.4K |
Get alerted when CTOR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CITIUS ONCOLOGY, INC. including:
Top Institutional Holders of CTOR
ARMISTICE CAPITAL, LLC
$5.7M9,188,855 shBANK OF AMERICA CORP /DE/
$2.4M3,835,160 shVANGUARD CAPITAL MANAGEMENT LLC
$331.6K534,824 shGEODE CAPITAL MANAGEMENT, LLC
$164.1K264,733 shVANGUARD FIDUCIARY TRUST CO
$75.6K121,910 shIFP Advisors, Inc
$66.6K107,424 shBlackRock, Inc.
$29.4K47,454 shNORTHERN TRUST CORP
$28.4K45,746 shSTATE STREET CORP
$26.6K42,900 shUBS Group AG
$22.8K36,840 sh
| Fund | Value | Shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | $5.7M | 9,188,855 |
| BANK OF AMERICA CORP /DE/ | $2.4M | 3,835,160 |
| VANGUARD CAPITAL MANAGEMENT LLC | $331.6K | 534,824 |
| GEODE CAPITAL MANAGEMENT, LLC | $164.1K | 264,733 |
| VANGUARD FIDUCIARY TRUST CO | $75.6K | 121,910 |
| IFP Advisors, Inc | $66.6K | 107,424 |
| BlackRock, Inc. | $29.4K | 47,454 |
| NORTHERN TRUST CORP | $28.4K | 45,746 |
| STATE STREET CORP | $26.6K | 42,900 |
| UBS Group AG | $22.8K | 36,840 |
More Healthcare Companies
View all Healthcare →Put CTOR on your watchlist
Track score changes the day CITIUS ONCOLOGY, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CTOR a good stock to buy?
13F Pro's AI-powered analysis of CITIUS ONCOLOGY, INC. (CTOR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CTOR are available on the CTOR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CTOR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CTOR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CITIUS ONCOLOGY, INC.'s investment landscape.